Topical issues of dabigatran use in combination antithrombotic therapy in patients with acute coronary syndrome and nonvalvular atrial fibrillation
Atrial fibrillation is the most common heart rhythm disorder. According to various sources, a third of patients with atrial fibrillation also suffer from coronary heart disease. Both acute coronary syndrome and PCI with stable IHD require the prescription of combined antithrombotic therapy, which in...
Main Authors: | N. A. Novikova, A. S. Shilova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«REMEDIUM GROUP» Ltd.
2020-06-01
|
Series: | Атеротромбоз |
Subjects: | |
Online Access: | https://www.aterotromboz.ru/jour/article/view/216 |
Similar Items
-
ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS
by: M. Yu. Gilyarov, et al.
Published: (2016-01-01) -
ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ДАБИГАТРАНА У ПОЖИЛЫХ БОЛЬНЫХ С НЕКЛАПАННОЙ ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ В РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕ (РЕЗУЛЬТАТЫ ИССЛЕДОВАНИЯ MEDICARE)
by: Н. М. Воробьева, et al.
Published: (2015-07-01) -
ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ДЛИТЕЛЬНОЙ ТЕРАПИИ ДАБИГАТРАНОМ ПРИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ
Published: (2014-12-01) -
NEW PROSPECTS OF ANTITHROMBOTIC THERAPY IN PATIENTS WITH ATRIAL FIBRILLATIO AND CORONARY ARTERY STENTS: DABIGATRAN POTENTIAL
by: M. Yu. GILYAROV, et al.
Published: (2017-12-01) -
Analysis of antithrombotic therapy of atrial fibrillation in international and Russian registries
by: O. V. Reshetko, et al.
Published: (2019-08-01)